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Late effects in adult survivors of childhood cancer:
the need for life-long follow-up
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Background: To assess health status and health-related quality of life (HRQoL) in childhood cancer survivors who
were not involved in regular long-term follow-up.
Patients and methods: One hundred and twenty-three long-term survivors, median age 33 (19–50) years, follow-
up 27 (9–38) years, were recalled to the long-term follow-up clinic. Most of them were treated in the period
1970–1990. Late effects were graded using the Common Terminology Criteria for Adverse Events, version 3
(CTCAEv3). HRQoL was assessed by RAND-36. Socio-economic factors were compared with data from Statistics
Netherlands (CBS).
Results: Grade 1–2 late effects were found in 54% of the survivors, grade 3–4 in 39%, two or more late effects in 70%
and grade 2–4 previously unknown late effects in 33%. Survivors had significantly lower scores on RAND-36
compared with controls.
Conclusions: As nearly 40% of these long-term childhood cancer survivors suffer from moderate to severe
late effects and 33% had previously unknown late effects it is worthwhile recalling these patients to follow-up. Where
and by whom this follow-up can best be done is still a question that needs to be answered.
Key words: childhood cancer survivors, grading of late effects, long-term follow-up, HRQoL
introduction
As a result of improved survival of childhood cancer there is
a growing population of long-term survivors [1]. This ever
enlarging population of young adult childhood cancer
survivors is at increased risk of considerable morbidity and
even mortality as a result of late adverse effects of their previous
treatment.
Adverse late effects secondary to previous treatment with
chemotherapy or radiation are common; as many as two-thirds
of survivors of childhood cancer will experience such late effects
[2–5]. All organ systems are at risk, with late effects including
cognitive impairment, infertility, alterations in growth and
development, organ system damage and second malignancies
[6, 7]. To ensure that survivors enjoy the best possible
quantity and quality of life it is important to recognize and
treat adverse effects if possible at an early stage [7]. Most
clinicians advocate that childhood cancer survivors should
be followed for life [8, 9]. However, at present not all
long-term survivors participate in long-term follow-up.
Many were discharged years ago and some doctors still
discharge survivors as soon as they reach adulthood. From
an analysis performed by the Children’s Cancer Survivors
Study Group (CCSS) it appeared that only 31% of survivors
who were 18–19 years of age at time of interview had been
seen by a health-care provider at a paediatric cancer centre
in the previous 2 years. This percentage steadily decreased
with age of the survivor, to 17% of those who were 35 years or
older [10]. These older survivors reach a period in life when
many common chronic diseases begin to arise. In addition,
certain cancer treatments in childhood may cause an earlier
or more accelerated course of these diseases, such as
cardiovascular disease, osteoporosis or second malignancy
[11]. Considering the risk of adverse late effects of treatment
our hospital set up a long-term follow-up (LTFU) clinic in
1995. Childhood cancer survivors made a transition from
the regular paediatric oncology clinic to this LTFU clinic as
soon as they had been off-treatment for 5 years. From 2004
we recalled adult survivors who in the past, mostly in the
period 1970–1990, had been discharged from the paediatric
oncology clinic, which in those days usually occurred if they
had no evidence of disease for 5–10 years. Assessment of
these adult survivors for possible adverse effects of treatment
was done by a general practitioner (GP) employed by the
paediatric oncology department and trained by the paediatric
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health status and health related quality of life (HRQoL) of all
survivors seen in the first year by the GP.
methods
patients
Patients were eligible for recall to the LTFU clinic if they had been treated
previously at the paediatric oncology department of the University Medical
Center Groningen, The Netherlands, were at least 5 years off-treatment
and were not yet involved in any childhood cancer follow-up in either the
same hospital or elsewhere. One hundred and thirty-three out of 210
eligible patients were chosen at random and recalled to the LTFU clinic
between May 2004 and May 2005. Ten of them (10%) refused for
several reasons, most often because they did not want to look back but
wanted to look forward and rebuild their life. The remaining 123
patients (66 males, 57 females) were seen by a doctor with special interest in
late effects. According to their diagnosis and treatment in the past, the
patients underwent risk-based evaluations such as hormonal assessments,
echocardiography, bone mineral density tests or pulmonary function
tests. Due to the fact that Dutch guidelines are still under development,
we followed the guidelines according to the practice statement ‘Therapy
Based Long Term Follow Up’ produced by the United Kingdom
Children’s Cancer Study Group (UKCCSG) Late Effects Group (LEG).
In addition patients who had received chest irradiation and therefore
were at risk for coronary disease underwent electron beam computed
tomography (EBCT), which is a non-invasive test to detect calcium
deposits in the coronary arteries. Coronary artery calcification is
expressed as a calcification score, the standard method is described by
Agatston et al. [12]. A total calcium score is determined by summing up
the individual scores from each of the four coronary arteries. The scores
are compared with the percentile ranks of Hoff et al. [13], which are
adjusted for age and gender.
Patients were diagnosed with childhood cancer between 1968 and 1997.
Patients with a central nervous system tumour were excluded because most
of them were followed separately by a multidisciplinary neuro-oncology
team. No significant differences were found in gender, diagnosis and age
at diagnosis between the study group and the 87 patients who were not yet
recalled. Characteristics of the participating patients are shown in Table 1.
Socio-economic factors of the study group were compared with an
age-matched group in the Dutch population, analysed by Statistics
Netherlands (CBS).
grading of late effects
Late effects were graded using the Common Terminology Criteria for
Adverse Events, Version 3 (CTCAEv3), developed by the National Cancer
Institute (NCI). The CTCAEv3 represents the first comprehensive,
multimodality grading system to include both acute and late effects [14].
The CTCAEv3 grades adverse effects from 0 to 4. Grade 1 effects are
minimal and usually asymptomatic. Grade 2 effects are moderate, are
usually symptomatic but do not impair activities of daily living. Grade 3
effects are considered severe, requiring more serious interventions. Grade 4
effects are potentially life threatening. Low-grade events (grades 1 and 2) are
considered tolerable and manageable and should be distinguished from
severe or very undesirable high-grade events (grade 3 and 4).
health related quality of life
HRQoL was assessed by RAND-36, which is an internationally used valid
and reliable generic self-report questionnaire. It contains eight different
subscales: Physical Functioning (PF), Social Functioning (SF), Role
limitations due to Physical problems (RP), Role limitations due to
Emotional problems (RE), Mental Health (MH), Vitality (VT), Bodily Pain
(BP) and General Health perception (GH). For each subscale, scores
were coded, summed up and transformed to a scale from 0 (worst health)
to 100 (best health) [15]. The questionnaire takes about 10 min to
complete. The instrument has been translated into Dutch [16] and has
been validated for the Dutch population [17]. RAND-36 has already
been used in several other studies for assessment of HRQoL in
childhood cancer survivors [18, 19]. Mean scores of the available Dutch
norm group aged 25–44 years (n = 416) were used as reference values.
statistics
Data were analysed by descriptive techniques using frequencies,
percentages, means and medians as appropriate. The one-sample t-test
was used to compare the mean RAND scores of the study group with the
mean scores of the Dutch control group. The one-sample t-test was also
used to compare socio-economic variables of the study group with an
age-matched control group from the Dutch population. Because of the
small study population, differences between cancer types were not analysed.
To investigate which variables predict survivors QoL, all significant
characteristics identified from univariate analysis were studied with
multiple linear regression analysis. A significance level of P < 0.05 was
applied in all analyses.
results
Sixty-six out of 123 (54%) patients had a mild late effect (grade
1 or 2) and 48/123 (39%) had a moderate to severe late effect
(grade 3 or 4) (Table 2). Almost 70% had two or more late
effects. Forty-one out of 123 patients (33%) were diagnosed
with a grade 2–4 late effect that was previously unknown and
that required treatment or closer surveillance (Table 3). Five
Table 1. Demographic and clinical data of 123 participating adult
survivors
Study group (n = 123) CBS
Patient characteristics
Age at study (years)a 33 (19–50)
Age at diagnosis (years)a 6 (0–20)
Time since diagnosisa 27 (9–38)
Maleb 66 (53.7)
Living with parentsb 24 (19.5)* 9%
Living with a partnerb 70 (56.9)
Childlessb 74 (60.2)* 50%
Type of cancerb
Leukaemia 56 (45.5)
Malignant lymphoma 21 (17.1)
Bone tumour 19 (15.4)
Soft tissue sarcoma 7 (5.7)
Wilms’ tumour 4 (3.3)
Langerhans cell histiocytosis 8 (6.5)
Other 8 (6.5)
Treatmentb
Chemotherapy only 45 (36.6)
Radiotherapy only 5 (4.1)
Chemo- and radiotherapy 71 (57.7)
Cranial radiation 55 (44.7)
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survivors had a second malignant tumour (meningioma,
oesophageal carcinoma and three basocellular carcinomas)
that had not been recognized before and eight patients had
a previously unknown growth hormone deficiency. Seven
patients, four with Hodgkin’s lymphoma, two with
non-Hodgkin’s lymphoma and one with a rhabdomyosarcoma,
who had been treated with chest radiation, underwent
electron beam tomography because they were at risk for
coronary artery disease. All of them had Agatston scores >90th
percentile ranks of Hoff et al. [13] and three (43%) had
Agatston scores >400. These patients were referred to the
cardiologist for further cardiac evaluation (Table 3). Patients
treated with a combination of chemo- and radiotherapy had
significantly (P < 0.001) more moderate to severe late effects
compared with patients treated with chemotherapy alone.
Survivors lived significantly more often with their parents
than an age-matched group from the Dutch population (19.5%
vs. 9%, P = 0.004) and were more often childless (60.2% vs.
50%, P = 0.024) (Table 1).
The RAND-36 was sent to all 123 participating survivors
before they visited the LTFU clinic, and was returned by 121
(98%) of them. The outcomes on the various subscales of the
RAND-36 for the study group and the Dutch control group are
shown in Table 4. Survivors showed lower HRQoL scores in
comparison to the control group on the subscales
PF (P = 0.033), SF (P = 0.009), VT (P = 0.003) and GH
(P = 0.000). Survivors who had no late effects, or only mild
late effects, have significantly better scores on the RAND
subscales PF (P = 0.023, P = 0.011), RP (P = 0.030, P = 0.044),
VT (P = 0.009) and GH (P = 0.003) than survivors who had
severe late effects. Survivors with a job had significant better
scores on the RAND subscales PF (P= 0.019) and GH (P = 0.017).
Living with a partner was related to higher scores on the subscales
RE (P = 0.027) and MH (P = 0.003).
Patients who received cranial radiation had unexpectedly
significant better scores on the RAND subscales GH and BP
compared with those who had not received cranial radiation.
discussion
This study shows that a substantial number (39%) of survivors
who were treated in the period 1970–1990 have moderate to
severe late effects with significantly lower quality of life as
expressed by scores on the RAND-36 and compared with
survivors who have no or only mild late effects. Thirty-three
per cent of these late effects were previously unknown and
required treatment or closer surveillance. Some of these late
effects, such as a meningioma, were diagnosed following
specific complaints and symptoms that were reported at the
long-term follow-up clinic and that had failed to be appreciated
until then. This suggests that education of patients as well as
physicians who might be involved in follow-up care of these
survivors is an important issue. Our results support the
importance of life-long follow-up by physicians with
knowledge of late effects. In addition more strategies have to
be developed to improve the knowledge of childhood cancer
survivors and non-specialist clinicians, such as for example
the UKCCSG’s ‘After cure package’. Research will continue
to have an important role in LTFU to develop reduced
treatment strategies for treatment of the primary disease, like
reduced doses of radiation and chemotherapy, less toxic
chemotherapy and addition of cardioprotectants, which can
maintain high cure rates with less late toxicity.
Detection and treatment of problems that would otherwise
be neglected or detected much later may improve patients’
future quality of life. The data from the current study confirm
the findings of other studies that a significant proportion of
childhood cancer survivors have moderate to severe late effects
that require treatment, and affect their HRQoL [2, 20].
Table 2. Late effects graded with Common Terminology Criteria for
Adverse Events (CTCAE) version 3 in 123 survivors
Category n %
No late effect 9 7
Grade 1 or 2 66 54
Grade 3 or 4 48 39
Single late effect 29 24
Two or more late effects 85 69
Table 3. Previously undetected late effects that required therapy or
closer surveillance in 123 survivors
Category n %
Second malignancy 5 4%
Growth hormone deficiency 8 6%
Osteoporosis 7 6%
Arthrosis hip (osteonecrosis) 2 2%
Cardiac problem 10 8%
Reproductive problem 7 5%
Hepatitis C 1 1%
Thyroid problem 1 1%
Total 41 33%
Table 4. Means and standard deviations for the RAND-36 subscales, in
123 survivors and in Dutch controls (25–44 years)
Study group (n =123) Controls (n = 416)
Mean SD Mean SD
PF 85.9** 19.2 89.7 16.3
SF 84.7** 19.5 89.4 17.0
RP 79.5 32.5 82.7 32.2
RE 87.5 28.7 84.6 31.5
MH 77.2 15.9 77.9 17.7
VT 62.7** 20.1 68.2 18.9
BP 83.8 19.5 84.0 22.9
GH 67.2*** 22.6 75.9 20.2
**P < 0.01: survivors versus controls.
***P < 0.001: survivors versus controls.
SD, standard deviation; PF, physical functioning; SF, social functioning; RP,
role limitations due to physical problems; RE, role limitations due to
emotional problems; MH, mental health; VT, vitality; BP, bodily pain; GH,
general health perceptions.
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However, the percentages in our study are even higher than
those found by others who found approximately 30%
patients with moderate to severe late effects (versus 39% in
our study) and approximately 40% with two or more late
effects (versus 70% in ours) [2–4, 20]. Most research has
focused on the late effects during the first 10–15 years after
therapy. In our study time since diagnosis was longer than
20 years, which is longer than in most other studies. In an
earlier study we showed that the prevalence and the severity
of late effects increased with time since diagnosis [21]. As
time since diagnosis extends, medical problems associated
with aging may exhibit an earlier onset or more accelerated
course following certain cancer therapies. Oeffinger [11]
described that cancer survivors, diagnosed with cancer between
1970 and 1986, were more vulnerable to diseases that are
associated with aging, like second cancers, heart conditions,
kidney disease, musculoskeletal problems, osteoporosis and
sterility compared with their siblings. The incidence of
chronic conditions increases over time and does not appear to
plateau. Survivors lived significantly more often with their
parents and were more often childless than an age-matched
group from the Dutch population. Other studies confirm
these findings and they also find that a lower percentage of
survivors than peers are in employment [22, 23], which we
did not include in our study.
In our study, survivors who did not have a partner had
a lower quality of life, expressed as lower scores on the physical
functioning and general health perception subscales of the
RAND-36 and those without a job had lower scores on the role
limitations due to emotional problems and mental health
subscales. This might be explained by the fact that these
survivors lack emotional support from a partner and are likely
to have lower incomes. In the CCSS studies survivors with low
household income were at risk for adverse health status [23].
Several limitations can be recognized in the interpretation of
the current study. The sample size was relatively small, limiting
analysis between cancer types or different treatment modalities.
Patients with CNS tumours were not included. This might have
caused an underestimation of late effects and an overestimation
of HRQoL, as these survivors generally exhibit more severe
treatment sequelae [19, 23, 24]. Quality of life was measured
by RAND-36, which is a generic outcome measure focusing
on HRQoL. RAND-36 has been used in several other studies
to determine HRQoL in adult childhood cancer survivors
[18, 19]. Specific questionnaires would probably be better to
measure the functioning of survivors, but validated
questionnaires designed for childhood cancer survivors in
particular are hardly available. Finally, some patients,
especially those with cognitive defects following cranial
irradiation, were not able to complete the RAND-36 correctly
and needed help from family members. This might have
influenced the outcome. One could speculate that family
members are probably positively biased with regard to their
kin’s quality of life. Apparently the RAND-36, as a self-report
questionnaire, is less suitable for patients with impaired
cognitive functions. This could be an explanation for our
finding that survivors treated with cranial radiation had
higher scores on the subscales bodily pain and general health
perception.
This study supports the fact that the growing population of
aging childhood cancer survivors can be viewed as a high-risk
population for an impaired health status and HRQoL and
supports the necessity of life-long follow-up.
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